Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments.

ABSTRACT: Glioblastoma Multiforme (GBM) is a devastating disease with a low survival rate and few efficacious treatment options. The fast growth, late diagnostics, and off-target toxicity of currently used drugs represent major barriers that need to be overcome to provide a viable cure. Nanomedicines (NMeds) offer a way to overcome these pitfalls by protecting and loading drugs, increasing blood half-life, and being targetable with specific ligands on their surface. In this study, the FDA-approved polymer poly (lactic-co-glycolic) acid was used to optimise NMeds that were surface modified with a series of potential GBM-specific ligands. The NMeds were fully characterised for their physical and chemical properties, and then in vitro testing was performed to evaluate cell uptake and GBM cell specifici

SUBMITTER: Duskey JT 

PROVIDER: S-EPMC9325049 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature